IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma. Horns JM, Beder T, Kunstner A, Barz MJ, et al. Blood 2026;148:856-866.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Horns JM, Beder T, Kunstner A, Barz MJ, et al. IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma. Blood 2026;148:856-866.
PMID: 41824395